AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ACDC Metals Ltd

0.050

0.000

Volume:95.63K

Turnover:4.78K

Market Cap:3.75M

PE:-5.30

High:0.050

Open:0.050

Low:0.050

Close:0.050

52wk High:0.160

52wk Low:0.036

Shares:74.93M

Float Shares:40.29M

Volume Ratio:1.11

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.009

EPS(LYR):-0.009

ROE:-6.71%

ROA:-2.92%

PB:0.37

PE(LYR):-5.30

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

Agree Realty (ADC): How New Financing and Upbeat Guidance Shape the Company's Value Proposition

Simply Wall St.

Fosun International Honored as "ESG Leading Enterprise" by Bloomberg Businessweek/Chinese Edition

Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ADC.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.05,"timestamp":1765516320000,"preClose":0.05,"halted":0,"volume":95626,"delay":0,"nameEN":"ACDC Metals Ltd","floatShares":40287509,"shares":74930755,"eps":-0.00943,"marketStatus":"Market Closed","change":0,"latestTime":"12-12 16:12:00 AEDT","open":0.05,"high":0.05,"low":0.05,"amount":4781,"amplitude":0,"askPrice":0.052,"askSize":100000,"bidPrice":0.043,"bidSize":125000,"shortable":3,"etf":0,"ttmEps":-0.00943,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1765753200000},"marketStatusCode":7,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.05,"openAndCloseTimeList":[[1765494000000,1765515600000]],"volumeRatio":1.1075130568441962,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":40287509,"roa":"-2.92%","roe":"-6.71%","lyrEps":-0.00943,"volumeRatio":1.1075130568441962,"shares":74930755,"dividePrice":0,"high":0.05,"amplitude":0,"preClose":0.05,"low":0.05,"week52Low":0.036,"pbRate":"0.37","psRate":"10.88","week52High":0.16,"institutionHeld":0,"latestPrice":0.05,"committee":0.111111,"eps":-0.00943,"divideRate":0,"volume":95626,"delay":0,"ttmEps":-0.00943,"open":0.05,"prevYearClose":0.055,"prevWeekClose":0.06,"prevMonthClose":0.068,"prevQuarterClose":0.065,"fiveDayClose":0.06,"twentyDayClose":0.065,"sixtyDayClose":0.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588035413","title":"Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035413","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588035413?lang=en_us&edition=fundamental","pubTime":"2025-12-02 17:00","pubTimestamp":1764666000,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration  has approved the investigational new drug  application for the Phase Ib/II CLINCH-2 study evaluating ATG-022  in combination with MSD's  anti-PD-1 therapy, KEYTRUDA , as well as ATG-022 in combination with pembrolizumab and chemotherapy.CLINCH-2 is a Phase Ib/II study that will be led by its principal investigator Prof. Lin Shen at Beijing Cancer Hospital, the lead trial center. The study is designed to evaluate two combination regimens in patients with CLDN18.2-positive, HER2-negative, and PD-L1-positive  unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-ind-approval-in-china-for-phase-ibii-study-of-atg-022-cldn18-2-adc-in-combination-with-keytruda-pembrolizumab--chemotherapy-302630014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS.AU","CRS","BK4080","ORR.AU","BK4218","IE00B66KJ199.SGD","ADC.AU","IE00B19Z4B17.USD","IE0031619046.USD","BK4187","IE00B7SZL793.SGD","LU0963586101.USD","PK","ADC","IND.AU","BK7095","LU2065731478.USD","IND","ORR","BK4181","BK4231","BK4006"],"gpt_icon":0},{"id":"2587951731","title":"Agree Realty (ADC): How New Financing and Upbeat Guidance Shape the Company's Value Proposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2587951731","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587951731?lang=en_us&edition=fundamental","pubTime":"2025-11-28 23:21","pubTimestamp":1764343291,"startTime":"0","endTime":"0","summary":"Agree Realty (ADC) just closed a $350 million unsecured term loan with a 5.5-year duration and an accordion feature that allows for further lender commitments. This signals both financial flexibility and strength and is catching the attention of investors seeking stable growth.\nSee our latest analysis for Agree Realty.\nThe new financing arrives alongside upbeat news: Agree Realty lifted its 2025 AFFO and investment guidance and continues to draw positive attention from both analysts and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-adc/agree-realty/news/agree-realty-adc-how-new-financing-and-upbeat-guidance-shape","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-adc/agree-realty/news/agree-realty-adc-how-new-financing-and-upbeat-guidance-shape","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADC","ADC.AU","BK4080","BK4231","BK7095"],"gpt_icon":0},{"id":"2585216418","title":"Fosun International Honored as \"ESG Leading Enterprise\" by Bloomberg Businessweek/Chinese Edition","url":"https://stock-news.laohu8.com/highlight/detail?id=2585216418","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585216418?lang=en_us&edition=fundamental","pubTime":"2025-11-21 09:00","pubTimestamp":1763686800,"startTime":"0","endTime":"0","summary":"This year, 12 companies were honored as \"ESG Leading Enterprises\" in Category I - market capitalization over HKD12 billion, all of which are major Hong Konglisted companies, includingHenderson Land, Sun Hung Kai Properties, Towngas, Hutchmed, China Telecom, China Unicom, and Bank of China .Looking back on the past, Fosun has always paid attention to the reform and development of the global policies in the field of sustainable development. It has established a robust ESG governance management system, embedding sustainability principles into its operations over the years. It has actively responded to national and global strategies in relation to sustainable development, ensured information security, promoted technology innovation, implemented \"dual carbon\" goals, protected the rights and interests of employees to promote sustainable management and value creation.Fosun adheres to an innovation-driven strategy, and the anticancer drugs developed by its Health segment have widely benefited ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fosun-international-honored-as-esg-leading-enterprise-by-bloomberg-businessweekchinese-edition-302622019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4211","BK7505","ADC","BK7141","BK6095","BK1230","BK7509","BFC.AU","5HG.SI","00656","BK7095","BK4231","ESG","BFC","ADC.AU","BK6509"],"gpt_icon":0},{"id":"2584243956","title":"Ajinomoto Bio-Pharma Services Wins \"Best ADC Preclinical Publication 2024\" Award for AJICAP® Technology at 2025 World ADC Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2584243956","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584243956?lang=en_us&edition=fundamental","pubTime":"2025-11-17 22:26","pubTimestamp":1763389560,"startTime":"0","endTime":"0","summary":"Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies. TOKYO, Nov. 17, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services , a leading provider of biopharmaceutical contract development and manufacturing services,today announced it has been named the winner of the \"Best ADC Preclinical Publication 2024\" at the 12th Annual World ADC Awards, recognizing the company's innovative research publication on the AJICAP linker technology.About Ajinomoto Bio-Pharma Services Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and United States, providing support across gene therapy, APIs, and both large and small molecule manufacturing. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including high potenc","market":"hk","thumbnail":"https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ajinomoto-bio-pharma-services-wins-best-adc-preclinical-publication-2024-award-for-ajicap-technology-at-2025-world-adc-awards-302617219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC.AU","BK7095","BK4080","ADC","BK4231"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ADC.AU\",params:#limit:6,delay:true,,,undefined,":[]}}